Imaging and biochemical predictive biomarkers of overall survival and treatment response in patients receiving 223Ra-dichloride treatment in clinical practice

Sabina Dizdarevic(Brighton and Sussex Medical School), Angus Robinson(Royal Sussex County Hospital), Maryam Jessop(University Hospitals Sussex NHS Foundation Trust), Achuth Hosur, Mark Aplin, Helen-Marie Cripps, A. Nikapota, Patrick Begley(University Hospitals Sussex NHS Foundation Trust)
Journal of Nuclear Medicine
May 1, 2016
Cited by 2

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
|BORIS (University Library Bern)|2022|311